NewCardio (NWCI) Stock Analysis & Winston Score
NewCardio, Inc. is a small medical technology company focused on heart health. It develops software tools that help doctors read and interpret electrocardiograms, which are the tests that measure electrical activity in the heart. Its main customers are hospitals, clinics, and healthcare providers who need more accurate ways to detect heart problems. The company earns revenue by licensing its cardiac analysis software to medical institutions. NewCardio operates primarily in the United States and is a very small company, with a market cap that rounds to essentially zero, meaning it has little financial scale compared to larger medical device firms. Its operating margin is deeply negative, which means it is spending far more than it earns — a serious concern for a company this size. The key risk is straightforward: NewCardio must find a way to grow revenue and reduce losses before it runs out of resources, as tiny healthcare software companies face intense competition from much larger, well-funded rivals.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (1/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.00
Market Cap: $0M
Sector: Healthcare
Industry: Medical - Devices

